AbbVie Inc. (NYSE:ABBV) said it will file for FDA approval of its hepatitis C combination therapy in the second quarter after a study found it cured 99 percent of patients after 12 weeks. AbbVie Inc (NYSE:ABBV) stock performance was -3.03% in last session and finished the day at $50.62. Traded volume was 9.15million shares in the last session and the average volume of the stock remained 6.69million shares. AbbVie Inc (NYSE:ABBV) insider ownership is 0.10%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO) on Apr. 1 announced the appointment of E.J. Brandreth as Vice President of Quality. He will be responsible for all quality and compliance functions for a company that is moving forward with numerous late and early stage clinical trials and scaling up manufacturing and other operational areas to support its broad pipeline of immunotherapies and DNA vaccines. Inovio Pharmaceuticals Inc (NYSEMKT:INO) dropped -5.73 percent to $2.96 Monday on volume of 9.97million shares. The intra-day range of the stock was $2.88 to $3.12. Inovio Pharmaceuticals Inc (NYSEMKT:INO) has a market capitalization of $709.24million.
Mylan Inc. (NASDAQ:MYL) rallied 1.5 percent on April 4 after news it may be interested in acquiring Meda AB. The positive stock performance may provide an incentive for companies to continue buying, he said. Mylan Inc (NASDAQ:MYL)’s stock on Apr 07, 2014 reported a decrease of -4.40% to the closing price of $48.40. Its fifty two weeks range is $27.66 -$57.52. The total market capitalization recorded $18.00billion. The overall volume in the last trading session was 10.58million shares. In its share capital, MYL has 371.91million outstanding shares.
Johnson & Johnson (NYSE:JNJ) was the recipient of a large growth in short interest during the month of January. As of March 14th, there was short interest totalling 28,349,984 shares, a growth of 11.8% from the February 28th total of 25,347,509 shares, ARN reports. On Monday, shares of Johnson & Johnson (NYSE:JNJ) dropped -0.54% to close the day at $97.89. Company return on investment (ROI) is 15.00% and its monthly performance is recorded as 4.90%. Johnson & Johnson (NYSE:JNJ) quarterly revenue growth is 6.79%.